IN SILICO IDENTIFICATION OF NOVEL DRUG TARGETS IN ACINETOBACTER BAUMANNII BY SUBTRACTIVE GENOMIC APPROACH

Meenu Goyal; Citu Citu; Nidhi Singh

doi:10.22159/ajpcr.2018.v11i3.22105

Authors

Meenu Goyal Department of Biotechnology, Central University of Haryana, Mahendergarh, Haryana, India
Citu Citu Department of Biotechnology, Central University of Haryana, Mahendergarh, Haryana, India
Nidhi Singh Molecular and Structural Biology Division, CSIR - Central Drug Research Institute, Lucknow, Uttar Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i3.22105

Keywords:

Acinetobacter baumannii, Multiple drug resistance, Essential proteins, Metabolic pathway analysis, Druggability, Novel drug target

Abstract

Â Objective: Multiple drug resistance (MDR) in bacteria, particularly Gram-negative bacilli, has significantly hindered the treatment of infections caused by these bacteria. This results in the need for identifying new drugs and drug targets for these bacteria. The objective of this study was to identify novel drug targets in Acinetobacter baumannii which has emerged as a medically important pathogen due to an increasing number of infections caused by it and its MDR property.

Methods: In our study, we implemented in silico subtractive genomics approach to identify novel drug targets in A. baumannii American type culture collection 17978. Various databases and online software were used to build a systematic workflow involving comparative genomics, metabolic pathways analysis, and drug target prioritization to identify pathogen-specific novel drug targets.

Results: First, 458 essential proteins were retrieved from a database of essential genes, and by performing BLASTp against Homo sapiens, 246 human non-homologous essential proteins were selected of 458 proteins. Metabolic pathway analysis performed by Kyoto Encyclopedia of Genes and Genomesâ€“Kyoto Automatic Annotation Server revealed that these 246 essential non-homologous proteins were involved in 66 metabolic pathways. Among these metabolic pathways, 12 pathways were found to be unique to Acinetobacter that involved 37 non-homologous essential proteins. Of these essential non-homologous proteins, 19 proteins were found in common as well as unique metabolic pathways and only 18 proteins were unique to Acinetobacter. Finally, these target proteins were filtered to 9 potential targets, based on subcellular localization and assessment of druggability using Drug bank, ChEMBL, and literature.

Conclusion: Our study identified nine potential drug targets which are novel targets in A. baumannii and can be used for designing drugs against these proteins. These drugs will be pathogen specific with no side effects on human host, as the potential drug targets are human non-homologous.

Downloads

Download data is not yet available.

Author Biography

Meenu Goyal, Department of Biotechnology, Central University of Haryana, Mahendergarh, Haryana, India

Assistant Professor. Department of Biotechnology

References

Arora D, Jindal N, Romit KR. Emerging antibiotic resistance in Pseudomonas aeruginosa. Int J Pharm Pharm Sci 2011;3:82-4.

Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008;197:1079-81.

Spellberg B, Bonomo RA. The deadly impact of extreme drug resistance in Acinetobacter baumannii. Crit Care Med 2014;42:1289-91.

Villar M, Cano ME, Gato E, Garnacho-Montero J, Miguel Cisneros J, RuÃz de AlegrÃa C, et al. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: A reappraisal. Medicine (Baltimore) 2014;93:202-10.

Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: Epidemiology and management. Curr Opin Infect Dis 2010;23:332-9.

Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, et al. Acinetobacter baumannii: An emerging multidrug-resistant pathogen in critical care. Crit Care Nurse 2008;28:15-25.

Bayuga S, Zeana C, Sahni J, Della-Latta P, el-Sadr W, Larson E, et al. Prevalence and antimicrobial patterns of Acinetobacter baumannii on hands and nares of hospital personnel and patients: The iceberg phenomenon again. Heart Lung 2002;31:382-90.

Gusten WM, Hansen EA, Cunha BA. Acinetobacter baumannii pseudomeningitis. Heart Lung 2002;31:76-8.

Choi CH, Lee EY, Lee YC, Park TI, Kim HJ, Hyun SH, et al. Outer membrane protein 38 of acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell Microbiol 2005;7:1127-38.

Gaddy JA, Actis LA. Regulation of Acinetobacter baumannii biofilm formation. Future Microbiol 2009;4:273-8.

Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin JH, et al. Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins. FEMS Microbiol Lett 2009;301:224 31.

Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, et al. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun 2010;78:1952-62.

Camarena L, Bruno V, Euskirchen G, Poggio S, Snyder M. Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog 2010;6:e1000834.

Cerqueira GM, Peleg AY. Insights into Acinetobacter baumannii pathogenicity. IUBMB Life 2011;63:1055-60.

Butt AM, Tahir S, Nasrullah I, Idrees M, Lu J, Tong Y, et al. Mycoplasma genitalium: A comparative genomics study of metabolic pathways for the identification of drug and vaccine targets. Infect Genet Evol 2012;12:53-62.

Huynen MA, Diaz-Lazcoz Y, Bork P. Differential genome display. Trends Genet 1997;13:389-90.

Huynen M, Dandekar T, Bork P. Differential genome analysis applied to the species-specific features of Helicobacter pylori. FEBS Lett 1998;426:1-5.

Zhang R, Lin Y. DEG 5.0, a database of essential genes in both prokaryotes and Eukaryotes. Nucleic Acids Res 2009;37:D455-8.

Moriya Y, Itoh M, Okuda S, Yoshizawa AC, Kanehisa M. KAAS: An automatic genome annotation and pathway reconstruction server. Nucleic Acids Res 2007;35:W182-5.

Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017;45:D353-61.

Gardy JL, Spencer C, Wang K, Ester M, TusnÃ¡dy GE, Simon I, et al. PSORT-B: Improving protein subcellular localization prediction for gram-negative bacteria. Nucleic Acids Res 2003;31:3613-7.

Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34:D668-72.

Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, et al. ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012;40:D1100-7.

Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC. Structure of the mycobacterium tuberculosis D-alanine: D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrob Agents Chemother 2011;55:291-301.

Kovac A, Majce V, Lenarsic R, Bombek S, Bostock JM, Chopra I, et al. Diazenedicarboxamides as inhibitors of D-alanine-D-alanine ligase (Ddl). Bioorg Med Chem Lett 2007;17:2047-54.

Lacoste AM, Poulsen M, Cassaigne A, Neuzil E. Inhibition of d-alanyl-d-alanine ligase in different bacterial species by amino phosphonic acids. Curr Microbiol 1979;2:113-7.

Woodruff WW 3rd, Wolfenden R. Inhibition of ribose-5-phosphate isomerase by 4-phosphoerythronate. J Biol Chem 1979;254:5866-7.

Tanaka H, Oiwa R, Matsukura S, Inokoshi J, Omura S. Studies on bacterial cell wall inhibitors. X. Properties of phosph-N-acetylmuramoyl-pentapeptide-transferase in peptidoglycan synthesis of Bacillus megaterium and its inhibition by amphomycin. J Antibiot (Tokyo) 1982;35:1216-21.

Brandish PE, Burnham MK, Lonsdale JT, Southgate R, Inukai M, Bugg TD, et al. Slow binding inhibition of phospho-N-acetylmuramyl-pentapeptide-translocase (Escherichia coli) by mureidomycin A. J Biol Chem 1996;271:7609-14.

Gilmour R, Foster JE, Sheng Q, McClain JR, Riley A, Sun PM, et al. New class of competitive inhibitor of bacterial histidine kinases. J Bacteriol 2005;187:8196-200.

Zhang J, Zhang L, Li X, Xu W. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: A new class of antibacterial agents. Curr Med Chem 2012;19:2038-50.

Jackman JE, Raetz CR, Fierke CA. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of escherichia coli is a zinc metalloenzyme. Biochemistry 1999;38:1902-11.

Wu D, Kong Y, Han C, Chen J, Hu L, Jiang H, et al. D-alanine: D-alanine ligase as a new target for the flavonoids quercetin and apigenin. Int J Antimicrob Agents 2008;32:421-6.

Gotoh Y, Eguchi Y, Watanabe T, Okamoto S, Doi A, Utsumi R, et al. Two-component signal transduction as potential drug targets in pathogenic bacteria. Curr Opin Microbiol 2010;13:232-9.

Barrett JF, Hoch JA. Two-component signal transduction as a target for microbial anti-infective therapy. Antimicrob Agents Chemother 1998;42:1529-36.

Utsumi R, Igarashi, M. Two-component signal transduction as attractive drug targets in pathogenic bacteria. Yakugaku zasshi J Pharm Soc Jpn 2011;132:51-8.

Okada A, Gotoh Y, Watanabe T, Furuta E, Yamamoto K, Utsumi R. [19]-Targeting two-component signal transduction: A novel drug discovery system. Methods Enzymol 2007;422:386-95.

Watanabe T, Okada A, Gotoh Y, Utsumi R. Inhibitors targeting two-component signal transduction. Adv Exp Med Biol 2008;631:229-36.

Tiganova IG, Ilyina TS, Romanova YM. Two-component bacterial regulation systems: Targets of a search for new antibacterial drugs. Mol Genet Microbiol Virol 2014;29:93-103.

Stephenson K, Hoch JA. Developing inhibitors to selectively target two-component and phosphorelay signal transduction systems of pathogenic microorganisms. Curr Med Chem 2004;11:765-73.

Sass P, BrÃ¶tz-Oesterhelt H. Bacterial cell division as a target for new antibiotics. Curr Opin Microbiol 2013;16:522-30.

den Blaauwen T, Andreu JM, Monasterio O. Bacterial cell division proteins as antibiotic targets. Bioorg Chem 2014;55:27-38.

Hong W, Xie J. Progress of ftsZ inhibitors as novel antibiotics leads. Crit Rev Eukaryot Gene Expr 2013;23:327-38.

Chan FY, Sun N, Neves MA, Lam PC, Chung WH, Wong LK, et al. Identification of a new class of ftsZ inhibitors by structure-based design and in vitro screening. J Chem Inf Model 2013;53:2131-40.

Stokes NR, Baker N, Bennett JM, Berry J, Collins I, Czaplewski LG, et al. An improved small-molecule inhibitor of ftsZ with superior in vitro potency, drug-like properties, and in vivo efficacy. Antimicrob Agents Chemother 2013;57:317-25.

Domadia P, Swarup S, Bhunia A, Sivaraman J, Dasgupta D. Inhibition of bacterial cell division protein ftsZ by cinnamaldehyde. Biochem Pharmacol 2007;74:831-40.

Sun N, Chan FY, Lu YJ, Neves MA, Lui HK, Wang Y, et al. Rational design of berberine-based ftsZ inhibitors with broad-spectrum antibacterial activity. PLoS One 2014;9:e97514.

Bigham EC, Gragg CE, Hall WR, Kelsey JE, Mallory WR, Richardson DC, et al. Inhibition of arabinose 5-phosphate isomerase. An approach to the inhibition of bacterial lipopolysaccharide biosynthesis. J Med Chem 1984;27:717-26.

Airoldi C, Sommaruga S, Merlo S, Sperandeo P, Cipolla L, Polissi A, et al. Targeting bacterial membranes: NMR spectroscopy characterization of substrate recognition and binding requirements of D-arabinose-5-phosphate isomerase. Chemistry 2010;16:1897-902.

Gourlay LJ, Sommaruga S, Nardini M, Sperandeo P, DehÃ² G, Polissi A, et al. Probing the active site of the sugar isomerase domain from E. Coli arabinose-5-phosphate isomerase via X-ray crystallography. Protein Sci 2010;19:2430-9.

De Leon GP, Elowe NH, Koteva KP, Valvano MA, Wright GD. An in vitro screen of bacterial lipopolysaccharide biosynthetic enzymes identifies an inhibitor of ADP-heptose biosynthesis. Chem Biol 2006;13:437-41.

Bugg TD, Lloyd AJ, Roper DI. Phospho-murNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Infect Disord Drug Targets 2006;6:85-106.

Ha S, Gross B, Walker S. E. Coli murG: A paradigm for a superfamily of glycosyltransferases. Curr Drug Targets Infect Disord 2001;1:201-13.

Ezhilarasan V, Sharma OP, Pan A. In silico identification of potential drug targets in Clostridium difficile R20291: Modeling and virtual screening analysis of a candidate enzyme MurG. Med Chem Res 2013;22:2692-705

Tripathi P, Tripathi V. Determination of murG transferase as a potential drug target in neisseria meningitides by spectral graph theory approach. In: Perspectives in Environmental Toxicology. : Springer International Publishing; 2017. p. 147-60.

Dineshkumar B, Vigneshkumar P, Bhuvaneshwaran SP, Mitra A. Advanced drug designing softwares and their applications in medical research. Int J Pharm Pharm Sci 2010;2:16-8.